EVOKEvoke Pharma Inc

Nasdaq evokepharma.com


$ 0.54 $ 0.06 (12.78 %)    

Friday, 19-Apr-2024 10:38:16 EDT
QQQ $ 418.40 $ -4.86 (-1.15 %)
DIA $ 379.28 $ 0.80 (0.21 %)
SPY $ 497.86 $ -1.57 (-0.31 %)
TLT $ 89.08 $ -0.28 (-0.31 %)
GLD $ 221.54 $ 1.52 (0.69 %)
$ 0.4788
$ 0.54
$ 0.00 x 0
$ 0.00 x 0
$ 0.54 - $ 0.54
$ 0.42 - $ 2.42
21,941
na
1.6M
$ 0.72
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-14-2024 12-31-2023 10-K
2 11-09-2023 09-30-2023 10-Q
3 08-10-2023 06-30-2023 10-Q
4 05-15-2023 03-31-2023 10-Q
5 03-21-2023 12-31-2022 10-K
6 11-09-2022 09-30-2022 10-Q
7 08-10-2022 06-30-2022 10-Q
8 05-10-2022 03-31-2022 10-Q
9 03-08-2022 12-31-2021 10-K
10 11-10-2021 09-30-2021 10-Q
11 08-12-2021 06-30-2021 10-Q
12 05-12-2021 03-31-2021 10-Q
13 03-11-2021 12-31-2020 10-K
14 11-10-2020 09-30-2020 10-Q
15 08-06-2020 06-30-2020 10-Q
16 05-12-2020 03-31-2020 10-Q
17 03-12-2020 12-31-2019 10-K
18 11-07-2019 09-30-2019 10-Q
19 08-08-2019 06-30-2019 10-Q
20 05-08-2019 03-31-2019 10-Q
21 03-06-2019 12-31-2018 10-K
22 11-13-2018 09-30-2018 10-Q
23 08-09-2018 06-30-2018 10-Q
24 05-14-2018 03-31-2018 10-Q
25 03-07-2018 12-31-2017 10-K
26 11-14-2017 09-30-2017 10-Q
27 08-14-2017 06-30-2017 10-Q
28 05-15-2017 03-31-2017 10-Q
29 03-15-2017 12-31-2016 10-K
30 11-09-2016 09-30-2016 10-Q
31 08-15-2016 06-30-2016 10-Q
32 05-11-2016 03-31-2016 10-Q
33 03-10-2016 12-31-2015 10-K
34 11-12-2015 09-30-2015 10-Q
35 08-13-2015 06-30-2015 10-Q
36 05-14-2015 03-31-2015 10-Q
37 03-04-2015 12-31-2014 10-K
38 11-13-2014 09-30-2014 10-Q
39 08-13-2014 06-30-2014 10-Q
40 05-13-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 evoke-pharma-announces-senior-leadership-transition-with-promotion-of-matthew-j-donofrio-to-chief-executive-officer-as-of-march-31-2024

Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) ...

 recap-evoke-pharma-q4-earnings
Recap: Evoke Pharma Q4 Earnings
03/14/2024 20:35:20

 evoke-pharma-q4-2023-gaap-eps-059-misses-050-estimate-sales-1676m-beat-1632m-estimate

Evoke Pharma (NASDAQ:EVOK) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.50...

 earnings-scheduled-for-march-14-2024

Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.

 laurence-w-lytton-reports-in-13g-filing-a-999-stake-in-evoke-pharma

https://www.sec.gov/Archives/edgar/data/1105806/000093583624000282/evok13g.htm

 evoke-pharma-has-priced-an-underwritten-public-offering-led-by-nantahala-capital-management-for-gross-proceeds-of-up-to-30m-million-which-includes-initial-upfront-funding-of-approximately-75m

The offering is comprised of (i) 11,029,411 shares of common stock (or pre-funded warrants in lieu thereof), (ii) 11,029,411 Se...

 why-wipro-shares-are-trading-higher-by-over-16-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of Wipro Limited (NYSE: WIT) rose sharply during Friday’s session after the company reported third-quarter financial res...

 why-vci-global-shares-are-trading-lower-by-around-30-here-are-20-stocks-moving-premarket

Shares of VCI Global Limited (NASDAQ: VCIG) fell sharply in pre-market trading after the company announced pricing of $2.75 mi...

 evoke-pharma-announces-fda-orange-book-listing-of-new-gimoti-patent

Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) ...

 why-beyond-air-shares-are-trading-lower-by-around-37-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Beyond Air, Inc. (NASDAQ: XAIR) dipped during Tuesday’s session following weak quarterly results.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION